We are live on ! Find out more

EVMN

Evommune Inc

EVMN

Market cap $512M

14.11 USD

+0.32

2.32%

At close Updated Aug 26, 4:00 PM EDT

Pre-market

After hours

13.83

-0.28

1.98%

1 day

2.32%

5 days

-4.4%

1 month

23.02%

3 months

-39.57%

6 months

-47.01%

Year to date

-18.49%

1 year

-30.25%

5 years

-30.25%

10 years

-30.25%

About: Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.

Employees: 48

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 11.1%

Neutral 55.6%

Negative 33.3%

Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights

PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the second quarter ended June 30, 2026, and provided a business update. "There are still no first-line oral options for patients suffering with AD that combine lesion control, itch relief and tolerability. That gap is where we.

Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights

Evommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis

PALO ALTO, Calif., & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced the first patient was dosed in its Phase 2b clinical trial evaluating a potent, highly selective oral small molecule antagonist of MRGPRX2, EVO756, for the prophylactic treatment of migraine. "Initiating this migraine trial is an exciting mileston.

Evommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis

Evommune, Inc. (EVMN) Securities Fraud Investigation - Levi & Korsinsky

Evommune stock dropped approximately 38% after EVO756 missed its Phase 2b primary endpoint in chronic spontaneous urticaria, erasing millions in shareholder value in a single session. NEW YORK, July 7, 2026 /PRNewswire/ -- Evommune, Inc. (NYSE: EVMN) shareholders lost approximately 38% of their investment value on June 29, 2026, when the Company disclosed that its lead drug candidate EVO756 failed to meet the primary endpoint -- mean change in UAS7 at 12 weeks -- in its Phase 2b trial for moderate-to-severe chronic spontaneous urticaria (CSU).

Evommune, Inc. (EVMN) Securities Fraud Investigation - Levi & Korsinsky

Evommune's Healthy Balance Sheet Buys Them Time For AD

Evommune, Inc.'s recent miss with EVO756's CSU indications is a major setback. I agree that this creates doubts about the rest of EVMN's pipeline because the same biology now needs cleaner data in AD and migraine. However, remember that EVO301 still gives EVMN another catalyst after their positive Phase 2a AD data.

Evommune's Healthy Balance Sheet Buys Them Time For AD

Evommune, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Evommune, Inc. (EVMN)

Evommune's CEO and CSO sold shares on June 22, 2026, under Rule 10b5-1 plans adopted months earlier -- days before the Company disclosed that EVO756 failed its Phase 2b primary endpoint. NEW YORK, June 30, 2026 /PRNewswire/ -- Evommune, Inc. (NYSE: EVMN) shares dropped approximately 38% after the Company announced that its lead drug candidate EVO756 failed to meet the primary endpoint in a Phase 2b trial evaluating the treatment in adults with moderate-to-severe chronic spontaneous urticaria.

Evommune, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Evommune, Inc. (EVMN)

Zacks Investment Research

EVMN Stock Tanks as Phase IIb Urticaria Study Misses Primary Goal

Evommune shares fall after its phase IIb CSU study misses the primary endpoint, prompting the company to halt further development of EVO756 for the indication.

EVMN Stock Tanks as Phase IIb Urticaria Study Misses Primary Goal

This AAR Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

This AAR Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday

Evommune's Skin Disorder Study Falls Short

Read Also: Evommune Stock Cools Off After Big Rally On Successful Eczema Trial

Evommune's Skin Disorder Study Falls Short

Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria

PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced top-line results from its randomized, double-blind, placebo controlled, dose-ranging Phase 2b trial evaluating the efficacy and safety of oral MRGPRX2 antagonist, EVO756, in adults with moderate-to-severe chronic spontaneous urticaria (CSU).The Phas.

Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria

Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights

PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the first quarter ended March 31, 2026, and provided a business update. “We continue to make meaningful progress across our broad chronic inflammation targeted pipeline and remain on track to deliver top-line Phase 2b data for.

Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights

See News Rankings

Price charts implemented using Lightweight Charts™